{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:48:12Z","timestamp":1778856492204,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,10,29]],"date-time":"2007-10-29T00:00:00Z","timestamp":1193616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:\u2002<\/jats:bold>\n                    Interventions that preserve or increase beta\u2010cell mass may also prevent type 2 diabetes. Rosiglitazone prevents diabetes in people with high glucose levels who have impaired glucose tolerance and\/or impaired fasting glucose. The effect of this drug on both glucose levels and beta\u2010cell mass was studied in a rat model of diabetes, characterized by reduced beta\u2010cell mass at birth with normoglycaemia, and progression to dysglycaemia with age.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    Female Wistar rats were given either saline (vehicle) or nicotine during pregnancy and lactation. Offspring of saline\u2010exposed dams were given vehicle and offspring of nicotine\u2010exposed dams were randomized to receive either vehicle or rosiglitazone starting at weaning. Beta\u2010cell mass, proliferation and apoptosis were determined at birth and at 4 and 26\u2003weeks of age. Glucose homeostasis was examined following sequential oral glucose tolerance tests (OGTT).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Rosiglitazone treatment prevented the development of dysglycaemia in nicotine\u2010exposed animals. The ability of rosiglitazone to preserve normoglycaemia appeared to be because of its ability to increase beta\u2010cell mass through a combination of enhanced beta\u2010cell proliferation and decreased beta\u2010cell apoptosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    These results suggest that if rosiglitazone administration is started prior to the onset of glucometabolic abnormalities, it prevents the onset of dysglycaemia by partially restoring beta\u2010cell mass in animals with reduced beta\u2010cell mass at birth.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2007.00808.x","type":"journal-article","created":{"date-parts":[[2007,10,29]],"date-time":"2007-10-29T22:01:45Z","timestamp":1193695305000},"page":"763-771","source":"Crossref","is-referenced-by-count":18,"title":["Rosiglitazone prevents diabetes by increasing beta\u2010cell mass in an animal model of type 2 diabetes characterized by reduced beta\u2010cell mass at birth"],"prefix":"10.1111","volume":"10","author":[{"given":"A. C.","family":"Holloway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. E.","family":"Bruin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. C.","family":"Gerstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,8,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2005.01.003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104345"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s125-002-8248-z"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.9.2304"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020735"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00025.2004"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69420-8"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.11513"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2000.00099.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.5.1021"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00331.2003"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2003.11.021"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00128.2004"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0022-5"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-07-0050"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-005-3054-8"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0396"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0446"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0079"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.03.033"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2005.09.027"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-8329(01)00176-8"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2004.01.017"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0891-5849(94)00221-5"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1293.017"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","unstructured":"DonathMY EhsesJA MaedlerKet al.Mechanisms of beta\u2010cell death in type 2 diabetes.Diabetes2005;54(Suppl. 2):S108\u2013S113.","DOI":"10.2337\/diabetes.54.suppl_2.S108"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000178773.31525.c2"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-200403000-00001"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21845"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.2.482"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0155-1"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2007.00808.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2007.00808.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:04:12Z","timestamp":1761887052000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2007.00808.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,18]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1463-1326.2007.00808.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2007.00808.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,18]]}}}